Sign in
Taking people in United StatesNo phase

Tests a urine test for bladder cancer coming back in people already treated

Studies a urine test to check for return of non-muscle invasive bladder cancer.

Key facts

Who runs it
Early is Good Inc.
Where
Indianapolis, Little Rock, and St Louis, United StatesSee the 3 sites
Trial code
Registry title
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Status
Recruiting
People taking part
500 people, planned
Started
26 Jul 2023
Planned end
31 Aug 2026
Type of study
Observational
Record updated
23 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had non-muscle invasive bladder cancer diagnosed in the past 2 years and are having a routine check-up cystoscopy. It tests a urine test (BCDx) to detect cancer coming back.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Non-muscle invasive bladder cancer (NMIBC), newly diagnosed or recurrent, diagnosed within the past 2 years.
Earlier treatment
Must be having standard-of-care routine monitoring cystoscopy. No other prior treatment is required.

Main reasons for not taking part

  • Planning to have radical cystectomy
  • Planning to have chemotherapy-radiation for urothelial cell carcinoma
  • Cannot give legally effective informed consent
  • Cannot provide at least 30mL of voided urine

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Patients 18 Years and older
  • Patients who have been diagnosed with incident or recurrent NMIBC within the past 2 years and undergoing standard of care/routine monitoring cystoscopy
  • Patients who are able to provide legally effective informed consent
  • Patients who are able to provide minimum 30mL of voided urine

Who cannot take part

  • Patients planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma

Where in United States

  • Indiana University School of MedicineIndianapolis, United StatesContact: Hristos Kaimakliotis, MD (principal investigator)Taking people
  • Arkansas Urology Research CenterLittle Rock, United StatesContact: Marotte,Taking people
  • Washington UniversitySt Louis, United StatesContact: Eric Kim, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitoring solution.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Plain-language title
Tests a urine test for bladder cancer coming back in people already treatedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 April 2026